Get the Stockscreener App
38.56
4.15%
-1.67
Urogen Pharma Ltd stock is traded at $38.56, with a volume of 1.28M.
It is down -4.15% in the last 24 hours and up +37.71% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
See More
Previous Close:
$40.23
Open:
$40.04
24h Volume:
1.28M
Relative Volume:
1.59
Market Cap:
$1.88B
Revenue:
$140.49M
Net Income/Loss:
$-153.49M
P/E Ratio:
-14.00
EPS:
-2.7551
Net Cash Flow:
$-175.90M
1W Performance:
+1.42%
1M Performance:
+37.71%
6M Performance:
+81.46%
1Y Performance:
+163.39%
1-Day Range:
$38.27
$40.35
1-Week Range:
$36.55
$40.35
52-Week Range:
$13.79
$40.35
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
38.56 | 1.88B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Jefferies | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Form 4 Urogen Pharma Ltd For: 10 July By Investing.com - Investing.com Canada
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares - Investing.com
UroGen Pharma (URGN) CMO Mark Schoenberg sells 10,000 shares via Rule 10b5-1 plan - Stock Titan
(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial - simplywall.st
Form 144 UroGen Pharma Ltd. For: 9 July By Investing.com - Investing.com Nigeria
Affiliate files Form 144: UroGen (NASDAQ: URGN) sells two 10,000-share blocks - Stock Titan
Urogen Pharma stock hits 52-week high at $39.59 - Investing.com
Urogen Pharma stock hits 52-week high at $39.59 By Investing.com - Investing.com Canada
Urogen’s UGN-501 gains IND clearance for bladder cancer - BioWorld News
H.C. Wainwright reiterates UroGen Pharma stock rating on FDA clearance By Investing.com - Investing.com Canada
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen - ChartMill
Is UroGen Pharma (URGN) Undervalued Following FDA Clearance For UGN 501? - simplywall.st
Bladder Cancer Oncolytic Virus UGN-501 Cleared by FDA for Phase 1 Trials This Fall - Tech Times
UroGen Pharma secures FDA IND clearance for UGN-501 - grafa.com
UroGen Pharma (URGN) Receives FDA Clearance for IND of UGN-501 - GuruFocus
UroGen receives FDA clearance for bladder cancer trial By Investing.com - Investing.com South Africa
UroGen receives FDA clearance for bladder cancer trial - Investing.com
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - The Manila Times
UroGen wins FDA clearance to test bladder cancer virus in Phase 1 - Stock Titan
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
UroGen Pharma Ltd focuses on bladder cancer therapies as investors watch long-term prospects - ad-hoc-news.de
URGN stock stays tied to UroGen Pharma's pipeline - ad-hoc-news.de
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar - Sahm
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? - The Motley Fool
UroGen Pharma (URGN) Surges 4.24% as Shares Approach Key Resistance LevelCombination Correction - dars.gov.et
UroGen Pharma stock consolidates below 52-week high amid sustained bullish momentum - Traders Union
UroGen Pharma edges higher to $34.88 as leadership highlights integrity focus, UroGen Pharma - Traders Union
Urogen Pharma stock hits 52-week high at 36.12 USD By Investing.com - Investing.com Nigeria
Urogen Pharma stock hits 52-week high at 36.12 USD - Investing.com
Price to book forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
(URGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Price to book forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to earnings forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to book forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen settles with Teva over Jelmyto patent dispute - MSN
Enterprise value to revenue forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to earnings forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to EBITDA forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen Pharma Ltd. Actuals & Estimates (NASDAQ:URGN) - TradingView
URGN Forecast — Price Target — Prediction for 2027 - TradingView
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares By Investing.com - Investing.com Nigeria
Form 4 Urogen Pharma Ltd For: 24 June By Investing.com - Investing.com Australia
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares - Investing.com
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):